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This brief communication describes the findings from a randomised controlled trial in Vietnam that co-administration of measles
vaccine (MV) with 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix®, GSK) does not affect the immunogenicity of MV.
These findings are most relevant for low- and middle-income countries (LMICs) in Asia considering PCV introduction.
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INTRODUCTION
Measles is one of the most highly contagious human pathogens,
accounting for significant morbidity and mortality worldwide, with
the highest burden in low- and lower-middle-income countries1.
Routine measles vaccination for children, combined with mass
immunisation campaigns in countries with low routine coverage,
are key public health strategies to reduce global measles deaths.
However, the global vaccine coverage of two-dose measles
vaccine (MV) schedules (85 and 67% for first and second dose,
respectively) are well short of the recommended 95% coverage
needed to prevent outbreaks2. The recent global measles
outbreak has claimed more than 140,000 lives, mostly among
young children in the poorest countries2. In the first three months
of 2019, provisional data based on monthly reports to the World
Health Organization (WHO; as of April 2019) showed an almost
300% increase in the number of measles cases reported globally
compared with the same period in 20183. Such outbreaks
highlight the importance of immunisation and the maintenance
of high MV coverage in the country.
The Expanded Programme on Immunization (EPI) was estab-
lished in 1974 to improve vaccination rates against measles,
diphtheria, pertussis, tetanus, poliomyelitis and tuberculosis. Since
then many other vaccines have been added to the EPI schedule,
including Hepatitis B, yellow fever and Haemophilus influenzae
(Hib) conjugate vaccine, and more recently pneumococcal
conjugate vaccines (PCV) and rotavirus vaccine. Some of these
vaccines are given simultaneously (co-administered) to alleviate
logistical constraints related to vaccine delivery and also improve
vaccine coverage. The exact EPI schedule varies by country.
PCV protects against Streptococcus pneumoniae infection, a
leading cause of pneumonia and serious invasive diseases in
children under 5 years4. Two licensed PCVs, 10-valent (PCV10,
Synflorix; GSK) and 13-valent PCV (PCV13, Prevnar-13/Prevenar-13;
Pfizer), are available and are demonstrated to be safe and effective
in preventing vaccine-type pneumococcal diseases5. While these
vaccines are in use in many regions, PCV introduction in Asia has
been slow, in part due to the high vaccine cost, and also a lack of
local or regional data on the effect of PCV for the government to
consider PCV introduction. This is a priority as Asia, in particular
the South East Asia region has one of the highest burden of
pneumococcal disease globally with approximately 4.4 million
cases occurring each year4. One important consideration for
countries planning to introduce PCV is whether it will interfere
with the immunogenicity of other EPI vaccines. WHO recommends
PCV to be given as a three-dose schedule, either as a two-dose
primary series followed by a booster dose at 9–18 months (2+ 1)
or as a three-dose primary series without a booster dose (3+ 0),
for maximum efficacy. These schedules coincide with existing EPI
vaccines and so it is necessary to ensure that their addition does
not interfere with the immunogenicity and protection of any co-
administered vaccines.
In Vietnam, measles vaccination is given as two-dose schedule
under the EPI; MV (AIK-C strain, POLYVAC, Vietnam) at 9 months of
age and measles–rubella (MR) combination vaccine at 18 months
of age. As a booster dose of PCV may also be given at 9 months of
age, it is important to determine whether this has any unintended
consequences on MV immunogenicity. As a secondary analysis
within a randomised, single-blind controlled trial of alternative
PCV schedules in Vietnam (the Vietnam Pneumococcal Project)6,
we investigated whether co-administration of PCV10 with MV at
9 months of age interferes with the immunogenicity of MV.
RESULTS AND DISCUSSION
Blood samples were collected at 10 months of age, from 144
participants who received both MV and PCV10 and from 133
participants who received MV alone at 9 months of age. The
majority of participants in both groups were seropositive for
measles antibody response; 142 (98.6%, 95% CI: 95.1–99.8%) in the
MV-PCV10 group and 126 (94.7%, 95% CI: 89.5–97.9%) in the MV-
only group (Fig. 1a). Both groups had similar measles IgG
geometric mean concentrations (GMCs) [GMC 95% CI: MV-PCV10:
120 AU/mL (105.2–136.9) MV-only: 111.8 AU/mL (95.2–131.4),
P= 0.502] (Fig. 1b).
This is the first study in Asia to evaluate the co-administration of
PCV and MV. Our data demonstrate that co-administration of
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PCV10 and MV at 9 months of age does not affect the
immunogenicity of MV. In addition, the reporting rates of adverse
events were very low, following administration of either MV and
PCV10 or MV alone. Only 5/143 (3.5%, data not available for one
participant) people in the MV-PCV10 group and 2/133(1.5%) in the
MV-only group reported any fever, with no other adverse events
reported. The results of this study provide evidence for the
Vietnamese government and other countries in the region to
support the introduction of PCV10 in a schedule in which the
booster dose coincides with the first dose of MV.
PCV10 co-administration has previously been reported not to
impact on the immunogenicity or reactogenicity of other childhood
vaccines such as Infanrix™-IPV/Hib (diphtheria–tetanus–acellular
pertussis-inactivated poliovirus–H. influenzae type b) or Infanrix™
hexa (Infanrix™-IPV/Hib with hepatitis B antigens), and Rotarix™
(live attenuated human rotavirus vaccine)7–9. Data on the co-
administration of PCV and MV are limited, particularly for Asian
countries. A multi-site trial in Europe examined the co-
administration of PCV10 with a tetravalent vaccine containing
measles–mumps–rubella–varicella (MMRV, Priorix-TetraTM, GSK
Biologicals)10. The seroconversion rates for measles were over
97% following co-administration with either PCV10 or Infanrix™-
hexa, with similar measles antibody levels between both groups10.
However, there was not a group that received only MMRV for
comparison. A recent trial of PCV formulations containing
pneumococcal proteins in The Gambia administered MV at
9 months of age (along with yellow fever and oral polio vaccines),
and included groups that either received PCV10 in a 2+ 1 schedule
(with the booster dose co-administered with MV; M-Vac, Serum
Institute of India) or a 3+ 0 schedule11. Three months post-
vaccination, the proportion of measles antibody levels equal to or
above the seroprotective level were not statistically different
between the children in the 3+ 0 group [72.9% (95% CI: 62.9–81.5)]
and 2+ 1 group [84.0% (95% CI 75.0–90.8) in the 2+ 1 group].
Measles GMC antibody levels and reactogenicity (injection site pain
being the most frequent, between 5 and 10%) were similar in both
groups. Although a different MV strain and population were
evaluated in this study compared to our study, the findings were
consistent in that no immune interference and no differences in
reactogenicity when PCV10 were co-administered with MV was
observed.
In conclusion, in line with other studies, we have demonstrated
a high measles seroconversion rate among children who received
both PCV10 and MV. Our results therefore support the co-
administration of PCV10 and MV at 9 months of age. These
findings are most relevant for LMICs in Asia that are considering
PCV introduction.
METHODS
Study design and participants
Two groups within the Vietnam Pneumococcal Project (ClinicalTrials.gov,
number NCT01953510) received PCV10 in either a 3+ 1 schedule (at 2, 3, 4
and 9 months of age), or a 3+ 0 schedule (at 2, 3 and 4 months of age).
Both groups received a first dose of MV at 9 months of age. Blood samples
were collected 4 weeks post-MV. Details of the study design have been
published previously6. All relevant ethical regulations for work with human
participants have been adhered; ethical approval has been obtained from
the Human Research Ethics Committee of the Northern Territory
Department of Health and Menzies School of Health Research (EC00153)
and the Vietnam Ministry of Health Ethics Committee and written informed
consent from the parent/legal guardian were obtained.
Measurement of measles IgG response
The MV IgG response was examined using a commercial chemilumines-
cence immunoassay (Diasorin, USA). The assay detection range is
5–300 AU/mL. The criteria for classifying MV IgG responses were: negative:
<13.5 AU/mL, equivocal: 13.5–16.5 AU/mL and positive: ≥16.5 AU/mL. The
positive cut-off value equates to 175mIU/mL based on the WHO Third
International Standard for Anti-Measles; a titre of ≥120mIU/mL by plaque
reduction neutralisation test (PRNT) is considered protective. A previous
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Fig. 1 Measles IgG responses at 10 months of age; 1 month after a dose of measles vaccine (MV) at 9 months of age. a Proportions of
positive, negative or equivocal measles IgG responses and b concentration of measles IgG responses. Dotted line represents 175mIU/mL
based on the WHO Third International Standard for Anti-Measles. PCV10 10-valent pneumococcal conjugate vaccine. Data presented as GMC
± 95% CI. GMC geometric mean concentrations, CI confidence interval.
Z.Q. Toh et al.
2
npj Vaccines (2020)    76 Published in partnership with the Sealy Center for Vaccine Development
1
2
3
4
5
6
7
8
9
0
()
:,;
study comparing this commercial immunoassay with PRNT has found that
samples in the equivocal range were >120mIU/mL12. The MV IgG GMCs
were log-transformed and compared using Student’s t-test.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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